Karyotype plus NPM1 mutation status defines a group of elderly patients with AML (≥60 years) who benefit from intensive post‐induction consolidation therapy-Reference-Cited by-同舟云学术

Karyotype plus NPM1 mutation status defines a group of elderly patients with AML (≥60 years) who benefit from intensive post‐induction consolidation therapy

Published:2016-11-08 Issue:12 Volume:91 Page:1239-1245
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol.

Author:

Sperr Wolfgang R.¹²,Zach Otto³,Pöll Iris³,Herndlhofer Susanne¹²,Knoebl Paul¹,Weltermann Ansgar³,Streubel Berthold⁴,Jaeger Ulrich¹²,Kundi Michael⁵,Valent Peter¹²

Affiliation:

1. Department of Internal Medicine I, Division of Hematology and HemostaseologyMedical University of ViennaVienna Austria

2. Ludwig Boltzmann Cluster Oncology, Medical University of ViennaVienna Austria

3. Department of Internal Medicine IHospital of the ElisabethinenLinz Austria

4. Department of Obstetrics and GynecologyMedical University of ViennaVienna Austria

5. Institute of Environmental Health, Medical University of ViennaVienna Austria

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.24560

Reference53 articles.

1. ACUTE MYELOID LEUKEMIA: TREATMENT OVER 60

2. Acute myeloid leukemia in the real world: why population-based registries are needed

3. Treatment concepts for elderly patients with acute myeloid leukemia

4. How I treat the older patient with acute myeloid leukemia

5. High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Updates in molecular genetics of acute myeloid leukemia;Seminars in Diagnostic Pathology;2023-05

2. A precision medicine classification for treatment of acute myeloid leukemia in older patients;Journal of Hematology & Oncology;2021-06-23

3. Treatment options for older unfit patients with acute myeloid leukemia;Future Oncology;2021-03

4. NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy;Blood Advances;2019-03-22

5. MDM2- and FLT3-inhibitors in the treatment of FLT3-ITD acute myeloid leukemia, specificity and efficacy of NVP-HDM201 and midostaurin;Haematologica;2018-07-05